Our scientific team, alongside our founder and Chief Scientific Officer Christoph Esslinger, has just published a paper in MDPI Viruses, describing the advanced capabilities of our DROPZYLLA® platform in rapidly and selectively identifying potent SARS-CoV-2 neutralising antibodies and to facilitate the drug discovery process. This paper shows that our DROPZYLLA® platform, besides traditional antibody discovery, is also well suited for antibody discovery in a rapid pandemic response setting. In such a context, like the COVID-19 pandemic, it has the capability to significantly speed up the development of therapeutic antibodies from bench to bedside. Read the full paper here:  https://lnkd.in/ebMxKqjW #MemoTherapeutics #MTx #Biotech #AntibodyDiscovery #InfectiousDiseases #DrugDiscovery

💡 Join KCAS Bio for a webinar exploring the evolving field of ADA (anti-drug antibody) assays. The featured speakers, Cheikh Kane, PhD and Dominic Warrino will cover the latest strategies for bioanalytical ADA/immunogenicity testing, including the impact of the new lean approach on preclinical and clinical programs. Gain insights from a historical overview of ADA assay concepts over the past decade, future strategies, and relevant case studies. The featured speakers will also discuss current protocols, best practices, and immunogenicity risk assessment. 🔗 REGISTER HERE: https://buff.ly/4dj7tDn #DrugDevelopment #ClinicalResearch #Immunogenicity #MonoclonalAntibodies #AnalyticalTesting #AntibodyDrugConjugate #BioanalyticalTesting #PreClinical #CellGeneTherapies

This #webinar will be highly informative on #ADA and #immunogenicity. Link below to sign up.

Working on ADCs? 𝐖𝐞𝐛𝐢𝐧𝐚𝐫 𝐨𝐧 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 20𝐭𝐡 𝐚𝐭 10 𝐀𝐌 𝐄𝐒𝐓! Discover insights from Darren Heywood (Promega) on plate-based assays for cell health screening, and hear from Abzena’s experts, Grant Harradence and Robert Francis, as they demonstrate: 𝘛𝘩𝘦 𝘪𝘮𝘱𝘢𝘤𝘵 𝘰𝘧 3𝘥 𝘤𝘦𝘭𝘭 𝘢𝘴𝘴𝘢𝘺𝘴 𝘪𝘯 𝘴𝘦𝘭𝘦𝘤𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘣𝘦𝘴𝘵 𝘈𝘋𝘊 𝘤𝘢𝘯𝘥𝘪𝘥𝘢𝘵𝘦𝘴 𝘏𝘰𝘸 𝘰𝘱𝘵𝘪𝘮𝘪𝘻𝘦𝘥 𝘣𝘪𝘰𝘢𝘴𝘴𝘢𝘺𝘴 𝘢𝘥𝘥𝘳𝘦𝘴𝘴 𝘬𝘦𝘺 𝘤𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦𝘴 𝘪𝘯 3D 𝘤𝘶𝘭𝘵𝘶𝘳𝘦𝘴 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘢𝘭 𝘦𝘹𝘢𝘮𝘱𝘭𝘦𝘴 𝘧𝘳𝘰𝘮 𝘵𝘸𝘰 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘈𝘋𝘊𝘴 𝘵𝘰 𝘨𝘶𝘪𝘥𝘦 𝘺𝘰𝘶𝘳 𝘰𝘸𝘯 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘫𝘰𝘶𝘳𝘯𝘦𝘺 Hopefully, you will gain actionable strategies to improve lead selection and achieve more reliable preclinical outcomes!

📢 We are thrilled to share the publication in OPRD of a new scientific article, "Route Design and Scale-Up of a Topoisomerase I Inhibitor Antibody–Drug Conjugate Payload," this paper results from the fruitful collaboration between William Goundry, Andrew Poulton and Matt Welham from AstraZeneca and Axplora Le Mans' team Bertrand Cottineau, Fanny Magne and Sandrine Ballot.   This publication emphasizes the development and scale-up activities conducted on a new #topoisomerase 1 inhibitor, a major class of ADC payload. It recognizes the expertise of our #ADC center of excellence in developing efficient and robust processes for our clients, benefitting patients with breakthrough therapies. Explore the article ➡ Link in comments   #Highpotency #FriedlanderReaction #RouteDesign #Topoisomerase1Inhibitor

The BD Monoclonal Center was the first one to combine FACS and monoclonal antibody techniques together at a commercial scale. Read the blog to learn more about how the history of FACS and BD Biosciences is intertwined.  https://lnkd.in/gK33AYGb #FactsaboutFACS #Flowcytometry #FACS #BDBiosciences

New publication! We’ve been working with John (Jay) Schneekloth, a leading expert in RNA-targeted drug discovery, to use our MAGNA technology to probe the interactions between the PreQ1 bacterial riboswitch and its natural ligand or a synthetic small molecule.   Published as a preprint on bioRxiv and submitted for publication in a high profile journal, the paper shows how we were able to use MAGNA to provide novel insights into the mechanisms of action of these two ligands upon the target RNA at a single molecule level.    We found that while both ligands stabilized the RNA structure, they did so through different mechanisms - a distinction that was not possible to detect using bulk measurement techniques.    These results demonstrate the capabilities of MAGNA to deliver valuable data about individual dynamic molecular interactions at scale, supporting lead selection in the development of novel RNA-targeted therapeutics.   Read the paper to get the full story: https://lnkd.in/df-tQb-9    #RNA #DrugDiscovery #DrugDevelopment #interactomics 

🎯#ADCs have traditionally focused on "celebrity" targets. However, while still slow, the trend is shifting towards novel targets, promising broader therapeutic applications. Advancements in antibody engineering are pivotal to this shift. In a recent Q&A with Doug Chapnick, Founder & CEO of BioLoomics, Rebecca Bair and I discussed these developments as well as exciting company updates! Our full interview with BioLoomics drops tomorrow. Stay tuned!!🔥 If you are interested in learning more about DeciBio's ADC tracker, TheraTrack, do not hesitate to reach out! We track all ADCs in development as well as their characteristics!! #biotechnews #precisionmedicine

Avidity Biosciences (RNA) leads in RNA therapeutics with Del-desiran (AOC 1001), targeting myotonic dystrophy type 1. Pivotal trial soon; approval could significantly boost earnings. Partnership with Bristol Myers Squibb, worth up to $2.3 billion, expands collaboration. Major clinical update for AOC 1001 expected by mid-2025; success could validate Avidity’s platform. Bullish on RNA above $24.00-$24.50, targeting $34.00-$35.00. Avidity's innovative approach presents significant growth potential. #AvidityBiosciences #RNA #Biotech #MyotonicDystrophy #ClinicalTrials #Innovation #Investing

Cancer is complex. One of the most challenging aspects is tumour heterogeneity: different cell sub-populations within a tumour having distinct characteristics, such as resistance to certain drugs. That can led to selection of resistant cell populations and, eventually, the failure of an intially effective treatment. Dual-payload ADCs are designed to tackle the problems of tumour heterogeneity. By conjugating two different drugs to a single antibody they are able to target diverse cell sub-populations and with multiple modes of action. It's therefore exciting to see Jerome Boyd-Kirkup of Hummingbird Bioscience presenting new preclincial data on their dual-payload ADC to PEGS Boston 2024.